Evidence map›Paper›PMID 41975095›Full record

ArticleNature structural & molecular biology2026

Comparative characterization of Cas12f orthologs reveals mechanistic features underlying enhanced genome editing efficiency.

Kaoling Guan, Rodrigo Fregoso Ocampo, Paula B Matheus Carnevali, Cindy J Castelle, Liliana Gonzalez-Osorio, Dominic T Castanzo, Nicole C Thomas, Molly Brothers, Tyler L Dangerfield, Matthew M Hooper and 10 more

Abstract readComparative Study
In one paragraph

Article in Nature structural & molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kaoling Guan *Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0001-6530-3705
Rodrigo Fregoso Ocampo *Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0009-0006-0951-8975
Paula B Matheus CarnevaliMetagenomi Therapeutics, Emeryville, CA, USA.
Cindy J CastelleMetagenomi Therapeutics, Emeryville, CA, USA.
Liliana Gonzalez-OsorioMetagenomi Therapeutics, Emeryville, CA, USA.
Dominic T CastanzoMetagenomi Therapeutics, Emeryville, CA, USA.
Nicole C ThomasMetagenomi Therapeutics, Emeryville, CA, USA.
Molly BrothersMetagenomi Therapeutics, Emeryville, CA, USA.
Tyler L DangerfieldDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0003-1413-2082
Matthew M HooperDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0002-4889-3288
Madeline S WestDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Nathan M ApplebyDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Isabella KrudopDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Rebecca C LamotheMetagenomi Therapeutics, Emeryville, CA, USA.
Daniela S Aliaga GoltsmanMetagenomi Therapeutics, Emeryville, CA, USA.
Lisa M AlexanderMetagenomi Therapeutics, Emeryville, CA, USA.ORCID http://orcid.org/0000-0003-0152-4554
Cristina N ButterfieldMetagenomi Therapeutics, Emeryville, CA, USA.
Kenneth A JohnsonDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Christopher T BrownMetagenomi Therapeutics, Emeryville, CA, USA.ORCID http://orcid.org/0000-0002-7758-6447
David W TaylorDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA. dtaylor@utexas.edu.ORCID http://orcid.org/0000-0002-6198-1194

Funding

Imaging macromolecular machines in gene regulationR35GM138348 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI TAYLOR, DAVID W · 2020 to 2024
$1.9M
Imaging macromolecular machines in gene regulationR35GM158551 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI David W Taylor · 2025 to 2026
$771k
NIGMS NIH HHS R35 GM138348NIGMS NIH HHS R35 GM158551
6 · The paper itself

Abstract

Miniature CRISPR-Cas12f nucleases are attractive candidates for therapeutic genome editing because of their compact size and compatibility with adeno-associated virus (AAV) delivery. However, editing efficiencies in mammalian cells are lower than those of larger systems. The extensive phylogenetic diversity of Cas12f suggests unexplored mechanistic variation with the potential for optimization. Here we identify and characterize a naturally occurring Cas12f ortholog discovered through metagenomics, Alistipes sp. Cas12f (Al3Cas12f), which supports robust genome editing in human cells. Through structural, biochemical and kinetic analyses, we compare Al3Cas12f to two recently described orthologs, Oscillibacter sp. Cas12f and Ruminiclostridium herbifermentans Cas12f. These orthologs present divergent architectures and regulatory features governing protospacer-adjacent motif recognition, guide RNA (gRNA) binding, dimerization and DNA cleavage. Notably, Al3Cas12f achieves efficient R-loop formation through a stable dimer interface and a naturally optimized gRNA. Leveraging these structural insights, we generate an engineered Al3Cas12f variant (RKK) that increases editing and improves activity across several tested genomic loci. By overcoming locus-dependent variability and an apparent potency threshold, this engineered compact editor seems to expand the feasibility of low-dose, AAV-compatible therapeutic genome editing. Our results elucidate mechanistic determinants of Cas12f activity and offer a framework for engineering compact genome editors that may bear therapeutic potential.

Indexed as

CRISPR-Associated ProteinsCRISPR-Cas SystemsHEK293 CellsHumansModels, MolecularR-Loop StructuresRNA, Guide, CRISPR-Cas SystemsCRISPR-Associated ProteinsRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID41975095
PMCPMC13186708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.